19 June 2013
Keywords: idenix, lowers, nm283, dosage, after, ae, reports
Article | 03 April 2006
Idenix Pharmaceuticals, a US biopharmaceutical company focused on viral and other infectious diseases, has modified its ongoing Phase IIb
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 April 2006
© 2013 thepharmaletter.com